Lung function · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Adverse events (not including serious adverse events): number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in adverse events (not including serious adverse events): number of… compared with aclidinium alone (moderate certainty).
1 finding from 1 review
Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol leads to lower exacerbations requiring steroids or antibiotics or both: number of… compared with formoterol (high certainty).
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in quality of life: number of participants with clinically significant… compared with formoterol (low certainty).
1 finding from 1 review
Change in depressive symptoms · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Adverse events (disease‐related: all physical symptoms); · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Change in quality of life · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Change in dyspnoea score · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Change in exercise tolerance · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Change in hospital utilisation ‐ not measured · chronic obstructive pulmonary disease (COPD) with depression
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Pneumonia, community acquired, at least 1 episode · patients with COPD
The intervention probably leads to lower pneumonia, community acquired, at least 1 episode (moderate certainty).
1 finding from 1 review
Intervention not reported
Pneumococcal pneumonia, at least 1 episode · patients with COPD
The intervention showed no clear difference in pneumococcal pneumonia, at least 1 episode (low certainty).
1 finding from 1 review
Intervention not reported
Death from cardiorespiratory causes · patients with COPD
The intervention showed no clear difference in death from cardiorespiratory causes (moderate certainty).
1 finding from 1 review
Intervention not reported
Death from all causes · patients with COPD
The intervention showed no clear difference in death from all causes (moderate certainty).
1 finding from 1 review
Intervention not reported
Hospital admission: any cause, at least 1 episode · patients with COPD
The intervention showed no clear difference in hospital admission: any cause, at least 1 episode (moderate certainty).
1 finding from 1 review
Intervention not reported
COPD exacerbation: at least 1 episode · patients with COPD
The intervention probably leads to lower COPD exacerbation: at least 1 episode (moderate certainty).
1 finding from 1 review
Intervention not reported
Lung function: FEV1 (L) · patients with COPD
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · Neonates with developing BPD
Inhaled steroids showed no clear difference in death or BPD at 36 weeks' postmenstrual age compared with systemic steroids (moderate certainty).
2 findings from 1 review
Diastolic blood pressure > 95th percentile at 7 years · Neonates with developing BPD
Inhaled steroids probably leads to lower diastolic blood pressure > 95th percentile at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review